Choice of Method for Type 2 Diabetes Mellitus Prevention: as Pathogenetic Approach Using Voglibose
Aim. Substantiation of necessity of pathogenetic approach to the choice of method for type 2 diabetes mellitus prevention on the basis of studying clinical efficiency and tolerability of voglibose in persons with impaired glucose tolerance (IGT). Methods. We have observed 25 persons with IGT in age from 35 to 55 years. Clinical examination included measuring of height, body mass, body mass index (BMІ), waist circumference (WC), blood pressure, heart rate, glucose tolerance test, determination of glycated haemoglobin level, parameters of blood lipids, random level of immunoreactive insulin with evaluation of insulin resistance (IR) index after НОМА-IR equation and total cardiovascular risk after SCORE scale. Persons with IGT received voglibose (Voksid, produced by Kusum Pharm LLC, Ukraine) in a dose of 0.2 mg before breakfast, dinner and supper during three months. In 3 months we have carried out reexamination with the assessment of metabolic effects of preparation and study of total cardiovascular risk dynamics. Results. Antihyperglycemic therapy with voglibose in a dose 0.6 mg/day lead to the reliable decline of all basic parameters of carbohydrate metabolism, body mass, BMI and WC parameters, total cholesterol, triglycerides and low-density lipoprotein cholesterol levels. On completion of research on a background of voglibose use, a significant decrease of total cardiovascular risk by 29 % was marked. Three months voglibose therapy did not result in the change of hepatic enzymes (alanine aminotransferase and aspartate aminotransferase) activity, as well as symptoms of hypoglycemia. Conclusions. Antihyperglycemic therapy with voglibose for three months contributes to statistically significant decline of postprandial hyperglycaemia, fasting glucose and IR index in persons with IGT and high cardiovascular risk. Target glycemic level were achieved in 82.6 % of patients. Under the influence of voglibose therapy, predicted risk of fatal complications due to cardiovascular diseases in the next 10 years was significantly reduced by 29 %.
Full Text:PDF (Українська)
Celik C., Tasdemir N., Abali R. et al. Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study // Fertil. Steril. — 2014 Apr. — 101(4). — 1123-8.e1; doi: 10.1016/j.fertnstert.2013.12.050. Epub 2014 Feb 4.
Huang Y., Cai X, Chen P. et al. Associations of prediabetes with all-cause and cardiovascular mortality: A meta-analysis // Ann. Med. — 2014 Sep 18. — 1-9. [Epub ahead of print]
Reis J.P., Loria C.M., Sorlie P.D. et al. Lifestyle factors and risk for new-onset diabetes: A population-based cohort study // Ann. Intern. Med. — 2011. — 155(5). — 292-299. doi:10.7326/0003-4819-155-5-201109060-00006.
Паньків В.І. Інгібітор альфа-глюкозидази воглібоз: нові можливості лікування і профілактики цукрового діабету // Міжнародний ендокринологічний журнал. — 2013. — № 7(55). — С. 35-38.
Kumar R.V., Sinha V.R. Newer insights into the drug delivery approaches of α-glucosidase inhibitors // Expert Opin. Drug Deliv. — 2012. — Vol. 9(4). — P. 403-416.
Takami K., Takeda N., Nakashima K. et al. Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes // Diabetes Care. — 2002. — Vol. 25(4). — P. 658-662.
Kawamori R., Tajima N., Iwamoto Y. et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance // Lancet. — 2009, May 9. — 373(9675). — 1607-14; doi: 10.1016/S0140-6736(09)60222-1. Epub 2009 Apr 22.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2020